Mutant B-Raf proto-oncogene (BRAF) and RAS, and RET fusions were found to be the disease-causing alterations in about 80% of tumours in PTC: oncogenic BRAF (~60% of cases), H-RAS and N-RAS (~10%) and RET fusions (~5%). Here, BRAF is linked to neoplasm.